CERBA-HEALTHCARE
9.11.2023 11:09:26 CET | Business Wire | Press release
Cerba HealthCare, a leading player in medical diagnostics, announces the appointment of Emmanuel Ligner as Chief Executive Officer of the Group. The Group has also strengthened its Supervisory Board with the appointment of Paul Navarre as Chairman and the appointments of Dr. Nuala Murphy and Benoît Ribadeau-Dumas. Their international track records and deep healthcare expertise will support the Group’s expansion in Europe, Africa and North America in clinical pathology for clinical trials, routine and specialty clinical pathology. Cerba HealthCare aims to remain at the forefront of medical innovation to help develop new treatments and improve patient health.
Emmanuel Ligner, Group Chief Executive Officer, said: « Cerba HealthCare is a leading company in the field of medical diagnostics as evidenced by the Group’s growth and the importance it has placed on innovation since its very inception. I am honored to join Cerba HealthCare at this key moment in its history where the expertise of the Group -ranging from routine clinical pathology to clinical pathology for assays- makes it possible to meet the challenges of the personalized medicine of tomorrow. I look forward to joining the management team and meeting with the employees. Together, we will build the next chapter of Cerba HealthCare. »
Paul Navarre, Chairman of the Supervisory Board, adds: « I am very pleased to join the Supervisory Board of Cerba HealthCare, which will invest all its energy and skills into the implementation of our international deployment strategy and the completion of the transformation plan already underway. With Emmanuel’s appointment, the Group is in an excellent position to carry out its growth strategy, powered by its ability to innovate and consolidate its positions across businesses and geographic markets. »
Jérôme Thill, Senior Advisor and former Chief Executive Officer of the Group, adds: « As I step down as Chief Executive Officer, I would like to thank all of Cerba HealthCare’s teams and partners. I wish Emmanuel Ligner and the whole team every success in their new roles. »
Emmanuel Ligner will join Cerba HealthCare on March 1st, 2024. Until then, Paul Navarre will act as the Group’s CEO, with the support of Jérôme Thill, as Senior Advisor, and of Philippe Buhl, as Managing Director.
####
Emmanuel Ligner has had a distinguished career in the healthcare sector. As Chairman and CEO of Cytiva (formerly GE HealthCare Life Sciences) since 2017, he has accelerated the growth trajectory of the group, which doubled sales in recent years. Before taking the helm at Cytiva, Emmanuel held a number of key positions in North America, Europe, the Middle East and Africa. Emmanuel began his career in the late 90s in Japan with Otsuka Pharmaceutical before joining Abbott.
Paul Navarre spent 30 years in management positions at Procter & Gamble, Allergan (President) and Ferring Inc (CEO). He is currently a member of the board of directors of several companies around the world (LEO Pharma, HTL, Hallura) and advises private equity funds.
Dr. Nuala Murphy, a neuroscientist by training, has held senior international positions in the pharmaceutical industry, most recently as President of Development and Commercialization at ICON Plc. In addition to joining the Supervisory Board of Cerba HealthCare, Nuala will take on the role of Executive Chair of Cerba Research.
Benoît Ribadeau-Dumas spent 15 years in senior management positions in the industry sector (Thales, CGG, Zodiac Aerospace), before becoming Chief of Staff to French Prime Minister Edouard Philippe from 2017 to 2020. Benoît is now Managing Director at Exor and a member of various boards, including Stellantis, Iveco, Institut Mérieux and Galileo Global Education.
####
About Cerba HealthCare
Cerba HealthCare, a leading global player in medical diagnostics, aims to support the evolution of health systems towards more prevention. It draws on more than 50 years of expertise in clinical pathology to better assess the risk of diseases development, detect and diagnose diseases earlier, and optimize the effectiveness of personalized medicine.
Every day, on five continents, the Group's 15,000 employees sustain the transformation of medicine, driven by one deep conviction: to advance diagnosis is to advance health.
Cerba HealthCare, enlightening health.
Additional information is available at www.cerbahealthcare.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231109943506/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom